The objective of the present study was to evaluate whether declarative memory deficits are related to executive function deficits (EF), since they could be a consequence of a poor organization of the material to memorize. This interaction between both cognitive processes can be studied simultaneously in a single task such as the Test of Memory Strategies (TSM). 23 patients with paranoid schizophrenic disorder, 11 with bipolar disorder with psychotic symptoms, 13 with bipolar disorder without psychotic symptoms and 15 healthy subjects were evaluated with the TSM; with the memory test Texts A and B (subtest of the Barcelona neuropsychological assessment battery), which assesses short-term and immediate recall without the influence of EF; and with the Trail Making Test (TMT): Part A (sustained attention) and Part B (executive control). The patients groups and the control group showed an improvement in memory performance across each of the TSM conditions. However, this facilitating effect of the strategies differed among the groups (the patients with higher EF deficits showed less improvement). Regarding these results, we conclude that this cognitive process cannot be independent of EF. However, due to the pilot nature of this study, it would be recommended to replicate these findings in new studies.
Background: This study aimed to explore the association between a verbal learning task that evaluates the potential mutual dependency between memory and executive functions (i.e., the Test of Memory Strategies, TMS) and cerebrospinal fluid (CSF) Alzheimer’s Disease (AD) biomarkers. Methods: A sample of 47 mild cognitive impairment (MCI) participants from Poland and Spain were classified according to the Erlangen Score Diagnostic Algorithm (ESA) into CSF- (n = 16) and CSF+ (n = 31) groups. Correlation analyses between TMS word-list conditions and CSF biomarkers were conducted. Additionally, an analysis of covariance was performed to define the effect on ESA classification in the sample, using as a covariable the country of origin of the participants. Results: Significant associations between the TMS-3 condition and Aβ42, t-tau, and p-tau were observed for the whole sample. In addition, the CSF- participants obtained higher cognitive performance in TMS-3 compared to the CSF+ group. This outcome persisted if the groups were based on Aβ42 scores, but not t-tau or p-tau values. Conclusions: These findings could indicate that poor performance on verbal learning tests may be affected by executive dysfunctions. Therefore, future intervention plans focused on training executive functions would be of interest to improve the ability of MCI patients to encode and organize information.
Predicting the evolution of individuals is a rather new mining task with applications in medicine. Medical researchers are interested in the progression of a disease and/or how do patients evolve or recover when they are subjected to some treatment. In this study, we investigate the problem of patients’ evolution on the basis of medical tests before and after treatment after brain trauma: we want to understand to what extend a patient can become similar to a healthy participant. We face two challenges. First, we have less information on healthy participants than on the patients. Second, the values of the medical tests for patients, even after treatment started, remain well-separated from those of healthy people; this is typical for neurodegenerative diseases, but also for further brain impairments. Our approach encompasses methods for modelling patient evolution and for predicting the health improvement of different patients’ subpopulations, i.e. prediction of label if they recovered or not. We test our approach on a cohort of patients treated after brain trauma and a corresponding cohort of controls.
Background: Diagnostic research criteria for Alzheimer’s Disease (AD) recommend the cerebrospinal fluid (CSF) as a sensible and validated biomarker to improve the accuracy of the prognosis regarding progression to dementia for people with mild cognitive impairment (MCI). Also, it has been established that episodic memory failure is a proxy for AD, while executive functions impairment could be leading to other types of dementia. One of the tests designed to simultaneously evaluate these cognitive functions with high sensitivity and specificity to discriminate between neurocognitive disorders is the Test of Memory Strategies (TMS). The main goals of the present study were 1) to assess the correlations between TMS and CSF markers (i.e., Aβ42, t‐tau, and p‐tau) in a sample of MCI patients, and 2) to provide additional validation for TMS as a clinical tool for Alzheimer’s Disease (AD) early detection.Method: 135 participants were recruited from a multicenter international study in Poland and Spain, but only 47 were selected (Mean age: 68.58 ± 10.03). The sample was split according to the Erlangen Score Diagnostic Algorithm (ESA) into: CSF ‐ (n = 11) and CSF + (n = 36). Correlations analyses between the five TMS word‐list conditions and CSF biomarkers were conducted, and analysis of covariance (ANCOVA) was performed to define the effect on ESA classification in the sample, using the site of origin of the participants as covariable.Results: Significant associations between the TMS‐3 condition and Aβ42, t‐tau, and p‐tau were observed for the whole sample. Also, the CSF‐ obtained a higher cognitive performance in the TMS‐3 than the possible AD group (CSF+).Conclusions: Our results revealed that combining CSF biomarker measures and TMS scores could contribute to a better characterization and a more precise approach to AD. Furthermore, considering that the TMS‐3 condition is mostly associated with executive functions, future interventions should focus on this cognitive construct and how it could affect the patient’s ability to encode and organize the information in memory.